Active Clinical Trials

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 60

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment

Study ID Numbers: 2011-0289|HRPO Log Number A-15872|NCI-2010-02375|W81XWH-10-1-0699

Study First Received: June 27, 2013

Last Updated: October 6, 2016

Estimated Primary Completion Date: December 2018


Primary Outcome Measures:

1-Year Progression Free Survival

Sponsors and Collaborators:

M.D. Anderson Cancer Center|U.S. Army Medical Research and Materiel Command|Memorial Sloan Kettering Cancer Center|Sellas Life Sciences Group

Website Link:

Leave a Reply

Call Now